IONS

Ionis Pharmaceuticals, Inc.

45.49 USD
+0.03 (+0.07%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Ionis Pharmaceuticals, Inc. stock is down -8.56% since 30 days ago. The next earnings date is May 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 March’s closed higher than February. In the last 10 Unusual Options Trades, there were 8 CALLs, 2 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
21 Feb 15:54 19 Jul, 2024 47.50 CALL 74 353
26 Feb 14:46 21 Jun, 2024 42.50 CALL 50 60
26 Feb 14:58 19 Jul, 2024 45.00 CALL 50 716
26 Feb 15:02 19 Apr, 2024 45.00 CALL 600 986
27 Feb 20:01 19 Jul, 2024 47.50 CALL 59 368
28 Feb 16:19 17 Jan, 2025 47.50 CALL 83 2
28 Feb 16:57 19 Jul, 2024 45.00 CALL 77 726
28 Feb 17:12 19 Jul, 2024 42.50 PUT 119 5
29 Feb 15:50 19 Apr, 2024 45.00 PUT 158 873
01 Mar 17:27 17 Jan, 2025 45.00 CALL 100 2

About Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy.

  • Oppenheimer
    Mon Feb 26, 08:38
    buy
    confirm
  • Piper Sandler
    Thu Feb 22, 13:47
    buy
    confirm
  • Needham
    Thu Feb 22, 05:10
    buy
    confirm